EXCLUSIVE: Trump’s former FDA nominee vowed new abortion pill safety review after pressure from Sen Hawley
Heidi Overton, a former nominee for Food and Drug Administration (FDA) commissioner, had committed to establishing a binding timeline and clear parameters for a safety study on the abortion medication mifepristone, the office of Sen.
- WHITE HOUSE PULLS TRUMP’S FDA PICK HEIDI OVERTON ON EVE OF SENATE PANEL VOTE "If confirmed, I would support completing that work as expeditiously as practicable while preserving the integrity of the scientific review," she added.
- "These are major pro-life wins that help ensure a robust study and the potential reinstatement of critical safeguards on the abortion drug that President Biden stripped away," Hawley said in a statement to Fox News Digital.
- "FDA has explained its intention to quickly complete its ongoing review using appropriate data and qualified experts, follow the evidence, and make the scientific basis and results public to the greatest extent permitted by law," Overton wrote in her Senate committee confirmation questionnaire prior to her nomination being pulled.
HAWLEY URGES DOJ PROBE INTO ABORTION PILL MAKER OVER SAFETY CONCERNS The FDA's review has faced repeated postponements despite earlier pledges by officials to release a study in 2025 amid concerns from critics that the agency was excluding critical data.
- FEDERAL APPEALS COURT BLOCKS MAILING OF ABORTION PILLS IN RULING WITH NATIONWIDE EFFECT Hawley's office noted that the potential study will analyze Medicaid and commercially available data spanning periods before and after the Biden administration lifted restrictions.
- Hawley, a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, has spent months pressing federal health officials for accountability over the delayed assessment.
- President Donald Trump hailed Overton as a "ROCKSTAR" in August when he picked the physician and White House advisor to succeed Marty Makary, who resigned in May.
- Federal oversight of the medication has drawn sustained scrutiny since 2023, when the Biden administration eliminated requirements mandating in-person doctor visits and in-person dispensing.
- Updated safety protocols would have applied to both brand-name mifepristone and its generic equivalents.
How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →